Clinical Study Results
See results of a 2-year clinical trial of LEMTRADA vs Rebif® (interferon beta-1a) as it relates to their effect on relapsing MS. See potential risks and benefits.
A 2-year clinical trial of people who had a relapse on an MS therapy
LEMTRADA: Proven to cut relapses in half over 2 years
The people taking LEMTRADA had nearly half as many relapses over 2 years compared to those taking Rebif.
The rate of relapses per year with LEMTRADA was 0.26 vs. 0.52 with Rebif.
LEMTRADA: Proven to help most people live relapse-free at 2 years
65% of people taking LEMTRADA were relapse-free at 2 years compared to 47% of people given Rebif.
A 2-year clinical trial of people who had never been on an MS therapy In this study, LEMTRADA was proven to cut relapses in half (55%) vs. Rebif. The rate of relapses per year with LEMTRADA was 0.18 vs. 0.39 with Rebif.
HOW LEMTRADA WAS STUDIED
- When LEMTRADA was being studied, researchers decided to measure LEMTRADA’s effectiveness and safety against Rebif 44 mcg, a commonly prescribed MS medication. Many other studies use a placebo, or no comparator drug at all
- This was done in two 2-year clinical trials with a total of 1191 people with relapsing MS that were chosen at random to receive either LEMTRADA or Rebif
- LEMTRADA was studied in both people who had a relapse on an MS therapy and in people who had never been on an MS therapy before
- Both studies included people who had experienced at least 2 relapses during the 2 years prior to the trial, and at least 1 relapse during the year prior to the trial
- Participants in Study 1 had to have rated 5.0 or lower on the Expanded Disability Status Scale (EDSS), while participants in Study 2 rated 3.0 or lower. EDSS measures disability progression in people with MS on a scale of 0 to 10, where 0 represents no disability
- In addition, participants in Study 1 had to have relapsed on interferon beta or glatiramer acetate